|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM272924393 |
| 003 |
DE-627 |
| 005 |
20231224235924.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231224s2017 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.3928/23258160-20170601-04
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n0909.xml
|
| 035 |
|
|
|a (DE-627)NLM272924393
|
| 035 |
|
|
|a (NLM)28613352
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Khan, Mehnaz
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Comparison of Ranibizumab and Bevacizumab for Macular Edema Secondary to Retinal Vein Occlusions in Routine Clinical Practice
|
| 264 |
|
1 |
|c 2017
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 13.09.2017
|
| 500 |
|
|
|a Date Revised 08.04.2022
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright 2017, SLACK Incorporated.
|
| 520 |
|
|
|a BACKGROUND AND OBJECTIVE: To determine outcomes of intravitreal ranibizumab (IVR) (Lucentis; Genentech, South San Francisco, CA) versus bevacizumab (IVB) (Avastin; Genentech, South San Francisco, CA) for treatment of macular edema (ME) secondary to retinal vein occlusion (RVO) in routine clinical practice
|
| 520 |
|
|
|a PATIENTS AND METHODS: A retrospective study identified treatment-naïve patients with ME secondary to RVO where treatment with either IVB or IVR was initiated. Retreatment criteria were based on ophthalmic examination and/or spectral-domain optical coherence tomography findings
|
| 520 |
|
|
|a RESULTS: Central RVO/hemi-RVO cohort: At 12 months, change in visual acuity (VA) (IVR: +12.9 letters, IVB +6.9 letters; P = .53), central subfield thickness (CST) (IVR: -144.1 μm, IVB: -153.9 μm; P = .88), and number of injections (IVR: 5.40 injections, IVB: 5.64 injections; P = .70) were not different between groups. Branch RVO cohort: At 12-month follow-up, no differences in change in VA (IVR: +15.2 letters, IVB: +10.6 letters; P = .46), CST (IVR: -23.1 μm, IVB: -91.4 μm; P = .16), or number of injections (IVR: 5.93 injections, IVB: 5.13 injections; P = .15) were noted
|
| 520 |
|
|
|a CONCLUSION: There is no notable difference in outcome between IVR and IVB when treating ME from RVO in routine clinical practice. [Ophthalmic Surg Lasers Imaging Retina. 2017;48:465-472.]
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
7 |
|a Angiogenesis Inhibitors
|2 NLM
|
| 650 |
|
7 |
|a Vascular Endothelial Growth Factor A
|2 NLM
|
| 650 |
|
7 |
|a Bevacizumab
|2 NLM
|
| 650 |
|
7 |
|a 2S9ZZM9Q9V
|2 NLM
|
| 650 |
|
7 |
|a Ranibizumab
|2 NLM
|
| 650 |
|
7 |
|a ZL1R02VT79
|2 NLM
|
| 700 |
1 |
|
|a Wai, Karen M
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Silva, Fabiana Q
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Srivastava, Sunil
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ehlers, Justis P
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Rachitskaya, Aleksandra
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Babiuch, Amy
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Deasy, Ryan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kaiser, Peter K
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Schachat, Andrew P
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yuan, Alex
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Singh, Rishi P
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Ophthalmic surgery, lasers & imaging retina
|d 2013
|g 48(2017), 6 vom: 01. Juni, Seite 465-472
|w (DE-627)NLM224956647
|x 2325-8179
|7 nnns
|
| 773 |
1 |
8 |
|g volume:48
|g year:2017
|g number:6
|g day:01
|g month:06
|g pages:465-472
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.3928/23258160-20170601-04
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_31
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_63
|
| 912 |
|
|
|a GBV_ILN_65
|
| 912 |
|
|
|a GBV_ILN_69
|
| 912 |
|
|
|a GBV_ILN_70
|
| 912 |
|
|
|a GBV_ILN_90
|
| 912 |
|
|
|a GBV_ILN_91
|
| 912 |
|
|
|a GBV_ILN_130
|
| 912 |
|
|
|a GBV_ILN_135
|
| 912 |
|
|
|a GBV_ILN_136
|
| 912 |
|
|
|a GBV_ILN_151
|
| 912 |
|
|
|a GBV_ILN_181
|
| 912 |
|
|
|a GBV_ILN_203
|
| 912 |
|
|
|a GBV_ILN_217
|
| 912 |
|
|
|a GBV_ILN_235
|
| 912 |
|
|
|a GBV_ILN_289
|
| 912 |
|
|
|a GBV_ILN_294
|
| 912 |
|
|
|a GBV_ILN_297
|
| 912 |
|
|
|a GBV_ILN_350
|
| 912 |
|
|
|a GBV_ILN_352
|
| 912 |
|
|
|a GBV_ILN_674
|
| 912 |
|
|
|a GBV_ILN_676
|
| 912 |
|
|
|a GBV_ILN_688
|
| 912 |
|
|
|a GBV_ILN_698
|
| 912 |
|
|
|a GBV_ILN_721
|
| 912 |
|
|
|a GBV_ILN_737
|
| 912 |
|
|
|a GBV_ILN_791
|
| 912 |
|
|
|a GBV_ILN_812
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 48
|j 2017
|e 6
|b 01
|c 06
|h 465-472
|